Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders.
Nature – The discovery that DNA methylation of different CpG sites can serve as digital barcodes of clonal identity led to the development of EPI-Clone,…
A senior regulator’s admission reveals uncomfortable truths about silence, ethics and trust inside the FDA.
The Trump administration has barred Harvard from allowing international students to enroll at the university.
Cancer took just about everyone in journalist Larry Ingrassia’s family, except him. His book unpacks his family’s multi-generational cancer mystery.
The manager of Harvard Medical School’s morgue has pleaded guilty to selling human remains.
A genetic twist in Ashkenazi Jewish men may both heighten cancer risk and unlock better treatment options.
Nature Communications – Personalized nanovaccines can elicit robust T-cell response but identifying tumour-specific antigens sometimes remains challenging. Here these groups identify IFN-γ as…
Oncotarget publications with an Altmetric Attention Score higher than 100
Some fun photos and sights from 2025 AACR/AACI Hill Day. The National Institutes of Health (NIH) National Cancer Institute (NCI) #AACRontheHill #FundNIH #AACIontheHill American Association…
Nature – The discovery that DNA methylation of different CpG sites can serve as digital barcodes of clonal identity led to the development of EPI-Clone,…
